Beyond Air Reports 107% FY26 Revenue Growth, Projects 110%+ FY27 Growth, Sees $1B Market for LungFit PH
XAIR sits 64% above its 52-week low of $0.335.
Summary
Beyond Air reported strong fiscal year 2026 revenue growth of 107% to $7.7 million, with Q4 revenue up 66% to $1.9 million. The company provided aggressive revenue guidance, projecting $8 million for the year ending December 31, 2026, and $16-$18 million (over 110% growth) for the year ending December 31, 2027. This follows a period of corporate restructuring and efforts to regain Nasdaq compliance, including a recently approved 1-for-20 reverse stock split. The company is awaiting FDA approval for a second-generation LungFit PH system, which could expand its addressable U.S. market by 4x to $400 million and worldwide to over $1 billion. This potential market expansion, coupled with strong growth projections, is highly material for the company's future.
At the time of this announcement, XAIR was trading at $0.55 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.1M. The 52-week trading range was $0.33 to $4.78. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.